Three of the early CETP inhibitors, namely torcetrapib, dalcetrapib, and evacetrapib, were unsuccessful in demonstrating a reduced risk of ASCVD for a variety of reasons in multiple large Phase III clinical trials. Here, CETP is linked to atherosclerosis.